Medicare Part D Subsidy Ends: How Pharma & Biotech Face a $3.6B Shift in Patient Costs

For biopharmaceutical companies, the end of the Medicare Part D premium subsidy signals a potential erosion of patient access and adherence, particularly for branded drugs used by the 25 million seniors in the program. As insurers adjust premiums and possibly formularies without the federal backstop, the industry must brace for volume shifts and a heightened focus on value-based contracting.

The Trump administration’s decision to terminate the temporary Medicare Part D premium subsidy program, as announced by the Centers for Medicare & Medicaid Services (CMS) on July 30, 2026, marks a pivotal shift in the landscape of prescription drug coverage for America’s 25 million Part D enrollees. Originally instituted by the Biden administration in 2024 as a bridge measure to mitigate near-term premium spikes resulting from the Inflation Reduction Act’s (IRA) comprehensive Part D redesign, the program has cost taxpayers an estimated $3.6 billion in fiscal year 2026 alone. Its expiration at the end of that year will reset the financial dynamics between insurers, beneficiaries, and the government, with the first visible impacts materializing in the fall 2027 plan year premiums announced during the November 2026 election season.

“

By 2026, the program was disbursing about $3.6 billion to insurers, according to CMS, and kept average monthly premiums about $10 lower than they would have been otherwise.

The subsidy program was born out of the IRA’s ambitious restructuring of the Part D benefit, which for the first time capped annual out-of-pocket drug costs at $2,000 for seniors and introduced inflation-linked rebates and drug price negotiation. These consumer protections, while long-term wins for affordability, created short-term actuarial challenges: insurers faced higher upfront liability without corresponding premium revenue, threatening to spike monthly premiums. The Biden-era subsidy directly compensated insurers for a portion of these costs, effectively smoothing the transition. By 2026, the program was disbursing about $3.6 billion to insurers, according to CMS, and kept average monthly premiums about $10 lower than they would have been otherwise.

CMS Administrator Dr. Mehmet Oz, in announcing the wind-down, argued that the subsidy had become a corporate handout, “funneling billions of taxpayer dollars to insurance companies,” and that the underlying market conditions had evolved. He projected that most beneficiaries would see monthly increases of less than $10, with some even experiencing decreases. However, critics, including Senate Minority Leader Chuck Schumer, described the move as an attack on seniors, aligning it with other healthcare affordability rollbacks like the sunsetting of enhanced ACA subsidies and Medicaid cuts.

The political calculus is acute. Medicare beneficiaries, who vote at disproportionately high rates, will learn their 2027 premium changes just as they go to the polls in November 2026. Any perceived premium shock—even if modest on average—could become a flashpoint in congressional races. The Democrat narrative of “raising costs on 25 million seniors” provides a potent campaign message.

From a market structure perspective, ending the subsidy reintroduces volatility into Part D pricing. Insurers will now need to fully price the IRA’s benefit enhancements without the federal backstop. That could widen the dispersion of premiums across plans, potentially leading to “sticker shock” for some enrollees, especially those in plans that competed aggressively on price during the subsidy era. The annual open enrollment period may see higher plan switching, as beneficiaries hunt for value. Meanwhile, the IRA’s permanent smoothing mechanisms, such as the $2,000 cap and manufacturer discounts in the catastrophic phase, remain intact, but they do not directly address the upfront premium setting.